Chardan lowered the firm’s price target on Metagenomi (MGX) to $11 from $12. The firm updated its model for Q2 financials and takes a slightly more conservative stance on programs/platform beyond hem A and the Ionis collaboration in light of the company’s increasing focus on pipeline execution and advancing gene editing platform competition. The firm noted its Q2 adjustments shift its price target lower.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGX: